Livin/ML-IAP as a new target for cancer treatment

Cancer Letters

Volumn 250, Issue 2, 2007, Pages 168-176

  Liu, Bin ^a   Han, Mei ^a   Wen, Jin Kun ^a   Wang, Ling ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cancer therapy; Caspase; KIAP; Livin; ML IAP

Indexed keywords

ANTIINFECTIVE AGENT; ETOPOSIDE; INHIBITOR OF APOPTOSIS PROTEIN; PEPTIDE; TUMOR VACCINE;

APOPTOSIS; CANCER INHIBITION; CANCER THERAPY; DRUG TARGETING; GENE EXPRESSION; HUMAN; IN VITRO STUDY; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; TUMOR CELL; TUMOR GROWTH;

EID: 34047100316     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.09.024     Document Type: Review

References (57)

1. Roy N., Mahadevan M.S., McLean M., Shutler G., Yaraghi Z., Farahani R., Baird S., Besner-Johnston A., Lefebvre .C., Kang X., Salih M., Aubry H., Tamai K., Guan X., Ioannou P., Crawford T.O., deJong P.J., Surh L., Ikeda J.E., Korneluk R.G., and MacKenzie A. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 80 (1995) 167-178
2. Rothe M., Pan M.G., Henzel W.J., Ayres T.M., and Goeddel D.V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83 (1995) 1243-1252
3. Liston P., Roy N., Tamai K., Lefebvre C., Baird S., Cherton-Horvat G., Farahani R., McLean M., Ikeda J.E., MacKenzie A., and Korneluk R.G. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 379 (1996) 349-353
4. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3 (1997) 917-921
5. Chen Z., Naito M., Hori S., Mashima T., Yamori T., and Tsuruo T. A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem. Biophys. Res. Commun. 264 (1999) 847-854
6. Richter B.W., Mir S.S., Eiben L.J., Lewis J., Reffey S.B., Frattini A., Tian L., Frank S., Youle R.J., Nelson D.L., Notarangelo L.D., Vezzoni P., Fearnhead H.O., and Duckett C.S. Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol. Cell Biol. 21 (2001) 4292-4301
7. Kasof G.M., and Gomes B.C. Livin, a novel inhibitor of apoptosis protein family member. J. Biol. Chem. 276 (2001) 3238-3246
8. Deveraux Q.L., and Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev. 13 (1999) 239-252
9. Miller L. An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol. 9 (1999) 323-328
10. Takahashi R., Deveraux Q., Tamm I., Welsh K., Assa-Munt N., Salvesen G.S., and Reed J.C. A single BIR domain of XIAP sufficient for inhibiting caspases. J. Biol. Chem. 273 (1998) 7787-7790
11. Sun C., Cai M., Gunasekera A.H., Meadows R.P., Wang H., Chen J., Zhang H., Wu W., Xu N., Ng S., and Fesik S.W. NMR structure and mutagenesis of the inhibitor of apoptosis protein XIAP. Nature 401 (1999) 818-822
12. Vucic D., Deshayes K., Ackerly H., Pisabarro M.T., Kadkhodayan S., Fairbrother W.J., and Dixit V.M. SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J. Biol. Chem. 277 (2002) 12275-12279
13. Vucic D., Stennicke H.R., Pisabarro M.T., Salvesen G.S., and Dixit V.M. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. 10 (2000) 1359-1366
14. Vucic D., Franklin M.C., Wallweber H.J., Das K., Eckelman B.P., Shin H., Elliott L.O., Kadkhodayan S., Deshayes K., Salvesen G.S., and Fairbrother W.J. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem. J. 385 (2005) 11-20
15. Eckelman B.P., and Salvesen G.S. The human anti apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J. Biol. Chem. 281 (2006) 3254-3260
16. Samuel T., Welsh K., Lober T., Togo S.H., Zapata J.M., and Reed J.C. Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and second mitochondrial activator of caspases. J. Biol. Chem. 281 (2006) 1080-1090
17. Riedl S.J., Renatus M., Schwarzenbacher R., Zhou Q., Sun C., Fesik S.W., Liddington R.C., and Salvesen G.S. Structural basis for the inhibition of caspase-3 by XIAP. Cell 104 (2001) 791-800
18. Liu Z., Sun C., Olejniczak E.T., Meadows R.P., Betz S.F., Oost T., Herrmann J., Wu J.C., and Fesik S.W. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 408 (2000) 1004-1008
19. Wu G., Chai J., Suber T.L., Wu J.W., Du C., Wang X., and Shi Y. Structural basis of IAP recognition by Smac/DIABLO. Nature 408 (2000) 1008-1012
20. Chai J., Du C., Wu J.W., Kyin S., Wang X., and Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406 (2000) 855-862
21. Franklin M.C., Kadkhodayan S., Ackerly H., Alexandru D., Distefano M.D., Elliott L.O., Flygare J.A., Mausisa G., Okawa D.C., Ong D., Vucic D., Deshayes K., and Fairbrother W.J. Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). Biochemistry 42 (2003) 8223-8231
22. Stucki J.W., and Simon H.U. Mathematical modeling of the regulation of caspase-3 activation and degradation. J. Theor. Biol. 234 (2005) 123-131
23. Silke J., Kratina T., Chu D., Ekert P.G., Day C.L., Pakusch M., Huang D.C., and Vaux D.L. Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. Proc. Natl. Acad. Sci. USA 102 (2005) 16182-16187
24. Ashhab Y., Alian A., Plliack A., Panet A., and Yehuda D. Two splicing variants of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett. 495 (2001) 56-60
25. Lin J.H., Deng G., Huang Q., and Morser J. KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem. Biophys. Res. Commun. 279 (2000) 820-831
26. Crnkovic-Mertens I., Semzow J., Hoppe-Seyler F., and Butz K. Isoform-specific silencing of the Livin gene by RNA interference defines Livin beta as key mediator of apoptosis inhibition in HeLa cells. J. Mol. Med. 84 (2006) 232-240
27. Gazzaniga P., Gradilone A., Giuliani L., Gandini O., Silvestri I., Nofroni I., Saccani G., Frati L., and Agliano A.M. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann. Oncol. 14 (2003) 85-90
28. Yagihashi A., Ohmura T., Asanuma K., Kobayashi D., Tsuji N., Torigoe T., Sato N., Hirata K., and Watanabe N. Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin. Chim. Acta 362 (2005) 125-130
29. Yagihashi A., Asanuma K., Tsuji N., Torigoe T., Sato N., Hirata K., and Watanabe N. Detection of anti-livin antibody in gastrointestinal cancer patients. Clin. Chem. 49 (2003) 1206-1208
30. Gong J., Chen N., Zhou Q., Yang B., Wang Y., and Wang X. Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas. J. Clin. Pathol. 58 (2005) 1081-1085
31. Takeuchi H., Morton D.L., Elashoff D., and Hoon D.S. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int. J. Cancer 117 (2005) 1032-1038
32. Xiang Y., Yao H., Wang S., Hong M., He J., Cao S., Min H., Song E., and Guo X. Prognostic value of Survivin and Livin in nasopharyngeal carcinoma. Laryngoscope 116 (2006) 126-130
33. Lee K.A., Kang J.W., Shim J.H., Kho C.W., Park S.G., Lee H.G., Paik S.G., Lim J.S., and Yoon D.Y. Protein profiling and identification of modulators regulated by human papillomavirus 16 E7 oncogene in HaCaT keratinocytes by proteomics. Gynecol. Oncol. 99 (2005) 142-152
34. Qiuping Z., Jei X., Youxin J., Wei J., Chun L., Jin W., Qun W., Yan L., Chunsong H., Mingzhen Y., Qingping G., Kejian Z., Zhimin S., Qun L., Junyan L., and Jinquan T. CC chemokine ligand 25 enhances resistance to apoptosis in CD4+ T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by means of livin activation. Cancer Res. 64 (2004) 7579-7587
35. Abe S., Yamamoto K., Hasegawa M., Inoue M., Kurata M., Hirokawa K., Kitagawa M., Nakagawa Y., and Suzuki K. Bone marrow cells of myelodysplastic syndromes exhibit significant expression of apollon, livin and ILP-2 with reduction after transformation to overt leukemia. Leuk. Res. 29 (2005) 1095-1096
36. Fischer U., and Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol. Rev. 57 (2005) 187-215
37. Yang Y., and Yu X. Regulation of apoptosis: the ubiquitous way. FASEB J. 17 (2003) 790-799
38. Carter B.Z., Gronda M., Wang Z., Welsh K., Pinilla C., Andreeff M., Schober W.D., Nefzi A., Pond G.R., Mawji I.A., Houghten R.A., Ostresh J., Brandwein J., Minden M.D., Schuh A.C., Wells R.A., Messner H., Chun K., Reed J.C., and Schimmer A.D. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 105 (2005) 4043-4050
39. Zhang M., Latham D.E., Delaney M.A., and Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24 (2005) 2474-2482
40. Kim E.H., Kim S.U., and Choi K.S. Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 24 (2005) 838-849
41. Demarchi F., and Brancolini C. Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies. Drug Resist Updat. 8 (2005) 359-368
42. Watson R.W., and Fitzpatrick J.M. Targeting apoptosis in prostate cancer: focus on caspases and inhibitors of apoptosis proteins. BJU. Int. 96 (2005) 30-34
43. Schmollinger J.C., and Dranoff G. Targeting melanoma inhibitor of apoptosis protein with cancer immunotherapy. Apoptosis 9 (2004) 309-313
44. Schmollinger J.C., Vonderheide R.H., Hoar K.M., Maecker B., Schultze J.L., Hodi F.S., Soiffer R.J., Jung K., Kuroda M.J., Letvin N.L., Greenfield E.A., Mihm M., Kutok J.L., and Dranoff G. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc. Natl. Acad. Sci. USA 100 (2003) 3398-3403
45. Hariu H., Hi rohashi Y., Torigoe T., Asanuma H., Hariu M., Tamura Y., Aketa K., Nabeta C., Nakanishi K., Kamiguchi K., Mano Y., Kitamura H., Kobayashi J., Tsukahara T., Shijubo N., and Sato N. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Clin. Cancer Res. 11 (2005) 1000-1009
46. Schimmer A.D., Dalili S., Batey R.A., and Riedl S.J. Targeting XIAP for the treatment of malignancy. Cell Death Differ. 13 (2006) 179-188
47. Schimmer A.D., and Dalili S. Targeting the IAP family of caspase inhibitors as an emerging therapeutic strategy. Hematology (2005) 215-219
48. Chi K.N., and Gleave M.E. Antisense approaches in prostate cancer. Expert Opin. Biol. Ther. 4 (2004) 927-936
49. Puri N., Eller M.S., Byers H.R., Dykstra S., Kubera J., and Gilchrest B.A. Telomere-based DNA damage responses: a new approach to melanoma. FASEB J. 18 (2004) 1373-1381
50. Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther. 12 (2005) 217-227
51. Hatano M., Mizuno M., and Yoshida J. Enhancement of C2-ceramide antitumor activity by small interfering RNA on X chromosome-linked inhibitor of apoptosis protein in resistant human glioma cells. J. Neurosurg. 101 (2004) 119-127
52. Zhang Q., Zhang Z.F., Rao J.Y., Sato J.D., Brown J., Messadi D.V., and Le A.D. Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas. Int. J. Cancer 111 (2004) 849-857
53. Yamaguchi Y., Shiraki K., Fuke H., Inoue T., Miyashita K., Yamanaka Y., Saitou Y., Sugimoto K., and Nakano T. Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Oncol. Rep. 14 (2005) 1311-1316
54. Yonesaka K., Tamura K., Kurata T., Satoh T., Ikeda M., Fukuoka M., and Nakagawa K. Small interfering RNA targeting surviv in sensitizes lung cancer cell with mutant p53 to adriamycin. Int. J. Cancer 118 (2006) 812-820
55. Crnkovic-Mertens I., Hoppe-Seyler F., and Butz K. Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene. Oncogene 22 (2003) 8330-8336
56. Tanabe H., Yagihashi A., Tsuji N., Shijubo Y., Abe S., and Watanabe N. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Lung Cancer 46 (2004) 299-304
57. Yagihashi A., Asanuma K., Kobayashi D., Tsuji N., Shijubo Y., Abe S., Hirohashi Y., Torigoe T., Sato N., and Watanabe N. Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. Lung Cancer 48 (2005) 217-221